Johnson & Johnson announces new Data showing Tremfya is the Only IL-23 to Deliver Durable Fistula remission Through 48 Weeks in Crohn's Disease With Perianal Fistula
October 20, 2026
October 20, 2026
RARITAN, New Jersey, Oct. 20 -- Johnson and Johnson Innovative Medicine issued the following news release:
* * *
Johnson & Johnson announces new data showing TREMFYA(R) (guselkumab) is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn's disease with perianal fistula
* TREMFYA maintained combined fistula remission through Week 48 across both maintenance dose regimens, including an increase from 28% at Week 24 to 35% at We . . .
* * *
Johnson & Johnson announces new data showing TREMFYA(R) (guselkumab) is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn's disease with perianal fistula
* TREMFYA maintained combined fistula remission through Week 48 across both maintenance dose regimens, including an increase from 28% at Week 24 to 35% at We . . .